Selected Grants
Safety, Efficacy, and Tumor Immune Microenvironment Changes with Neoadjuvant Chemotherapy and Cemiplimab with or without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2030DS7300-127 HAB08860
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2022 - 2027BMS 050
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2026MK-7902-009-00 LEAP-009
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2023 - 2025Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Clinical TrialPrincipal Investigator · Awarded by Merck · 2020 - 2025Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors including Non-Small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Memgen, Inc · 2022 - 2025A Phase 1 Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2021 - 2025A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2021 - 2024A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2020 - 2023A PHASE Ib DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATIONWITH ATEZOLIZUMAB, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LU
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2020 - 2023A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2017 - 2022A phase 1 / 2 multicenter study of BMS-986012 in subjects with relapsed/refractory small cell lung cancer.
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2022Evaluating the Impact of PCSK9 on the Composition of the Tumor-Immune Microenvironment and Treatment Response to Immune Checkpoint Blockade in NSCLC
FellowshipPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2021 - 2022Identifying Epigenetic Biomarkers that Predict Response to Immunotherapy in Lung Cancer Patients
ResearchMentor · Awarded by Lung Cancer Initiative of North Carolina · 2020 - 2022An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2022BMS CA 209-331-001 An Open label, Randomized Phase 3 Study of Nivolumab or Chemo
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2015 - 2022An open-label, randomized, phase 3 trial of Nivolumab vs Investigator's choice chemotherapy as first-line therapy for stge IV or recurrent PD-L1+non-small cell lung cancer
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2022A Randomized, Multicenter, Double- Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2022An open label, randomized phase 3 clincal trial of Nivolumab vs therapy of investigator's choice in recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2014 - 2022Strategies to overcome immunotherapy resistance in LKB1 and KEAP/NRF2 mutated NSCLC: modulating ferroptosis to restore immune sensitivity
FellowshipMentor · Awarded by Society for Immunotherapy of Cancer · 2020 - 2021A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca LP · 2019 - 2021A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Clinical TrialPrincipal Investigator · Awarded by Stem CentRx, Inc. · 2016 - 2020A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2020M16-298 (MERU)
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2020A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2018 - 2020A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca LP · 2015 - 2020A phase II, multi-center, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2015 - 2020TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by TESARO · 2019 - 2019BMS PROTOTYPE LUNG PROGRAM - 3 DAY PROGRAMMING
ConferencePrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2018 - 2019A phase II, multicenter, single-arm study of MPDL3280A in patients with advanced PD-L1_positive Locally advanced or Metastatic non-small cell lung cancer.
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2013 - 2018Evaluation of Tumor Infiltrating Lymphocytes in Resected Non Small Cell Lung Cancer
FellowshipMentor · Awarded by Lung Cancer Initiative of North Carolina · 2015 - 2018A Phase I study to evaluate the saftey, phamocokinetics and pharmacodynamics of JNJ-42756493 a pan-fibroblat growth factor receptor.
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2018Nivolumab with or without nab-Paclitaxel in previously treated, advanced stage, non-small cell lung cancer: a randomized Phase II study
Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2017 - 2018An Open-Label,Randomized Phase 3 trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2015 - 2018Phase I/II open label dose escalation study of the safety, pharmacokinetics, and preliminary efficacy of SCI6D6.5 as a single agent in patients with recurrent small cell lung cancer.
Clinical TrialPrincipal Investigator · Awarded by Stem CentRx, Inc. · 2013 - 2018Abbvie M14-361, A Phase I Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naive Extensive Stage Disease Small Cell Lung Cancer
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2015 - 2017Programs in Clinical Effectiveness of Cancer Pharmacogenomics
ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2012Refining and Validating Genomic Signatures in Lung Cancer
ResearchInvestigator · Awarded by National Institutes of Health · 2009 - 2010External Relationships
- AbbVie, Inc.
- Adnexis (Bristol-Myers Squibb)
- AstraZeneca
- Daiichi Sankyo Co., Ltd
- FLX/ RAPT Biotherapeutics
- Fosun Pharma
- Genentech, Inc (Roche Holding)
- Jazz Pharmaceuticals
- Johnson & Johnson
- Lilly
- Merck & Co. USA (not assoc'd with Merck KGaA)
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sanofi and Regeneron Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.